A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysms
We found that atorvastatin was safe and a dose up to 0.5 mg/kg/day for 6 weeks was well-tolerated in Japanese children with acute KD and CAAs.
Authors
- Shoko Imai (ORCID: https://orcid.org/0000-0002-8031-6835)
- Ken‐Ichi Imadome (ORCID: https://orcid.org/0000-0002-1662-4833)
- Kensuke Shoji (ORCID: https://orcid.org/0000-0002-7164-0262)
- Adriana H. Tremoulet (ORCID: https://orcid.org/0000-0001-9537-175X)
- Shinobu Kobayashi (ORCID: https://orcid.org/0000-0002-3606-1257)
- Eisuke Suganuma
- Kenji Furuno (ORCID: https://orcid.org/0000-0003-3991-8348)
- Zenpei Kano
- Jane C. Burns (ORCID: https://orcid.org/0000-0001-5679-1217)
- Chisato Shimizu
- Hiroshi Masuda (ORCID: https://orcid.org/0000-0001-5890-6647)
- Jumpei Saito
Institutions
- Jichi Medical University (JP)
- University of California San Diego (US)
- Saitama Children's Medical Center (JP)
- Fukuoka Children's Hospital and Medical Center for Infectious Diseases (JP)
- Japanese Red Cross Fukuoka Hospital (JP)
- National Center For Child Health and Development (JP)
Publication Details
- Journal
- Pediatrics International
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1111/ped.70104
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00